Elucidating the role of new RasGAP tumor suppressors in cancer

阐明新型 RasGAP 肿瘤抑制因子在癌症中的作用

• 批准号: 8767699
• 负责人: KAREN M CICHOWSKI
• 金额: $ 33.14万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-18 至 2019-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8767699
• 关键词: Biochemical; Breast; Breast Cancer Cell; Cell physiology; Cellular Assay; Clinical; Complex; Data; Development; Dimerization; Drug resistance; Endocrine; Exhibits; Family; Frequencies; Genes; Glioblastoma; Goals; Grant; Guanosine Triphosphate; HRAS gene; Hereditary Malignant Neoplasm; Human; Hydrolysis; Link; Malignant Neoplasms; Malignant neoplasm of prostate; Mammary Neoplasms; Maps; Methods; Molecular; Mus; Mutate; Mutation; NF1 gene; Nature; Neoplasm Metastasis; Oncogenic; Pathway interactions; Patients; Play; Process; Prognostic Marker; Prostate; Protein Isoforms; Proteins; Resistance; Role; Sampling; Signal Pathway; Signal Transduction; Syndrome; Tertiary Protein Structure; Therapeutic; Tumor Suppressor Proteins; Work; base; in vivo Model; insight; malignant breast neoplasm; novel; protein function; public health relevance; ras GTPase-Activating Proteins; ras Proteins; tumor

DESCRIPTION (provided by applicant): The Ras pathway is one of the most commonly deregulated pathways in human cancer. RAS genes are mutated in a broad spectrum of tumor types; however, RAS mutations are conspicuously absent in breast cancer, despite the fact that the pathway is hyperactivated. We have identified two RasGAP genes that appear to function as tumor suppressors in breast cancer. The goal of this application is to 1) understand how these proteins function and interact, 2) elucidate the mechanism by which these genes independently and cooperatively regulate breast cancer development, progression, and/or drug resistance, and 3) establish the frequency and clinical setting in which these genes are inactivated in human breast cancer. This work will serve as a basis for understanding why a subset of specific breast cancers progress, will elucidate novel aspects of Ras signaling, and will reveal how these new tumor suppressors link Ras to other signaling networks.

描述（由申请人提供）：RAS途径是人类癌症中最常见的失调途径之一。 RAS基因在各种肿瘤类型中被突变。然而，尽管该途径过度激活，但在乳腺癌中，RAS突变在乳腺癌中显然不存在。我们已经确定了两个RasGAP基因，它们似乎是乳腺癌中肿瘤抑制因子的作用。该应用的目的是1）了解这些蛋白质如何发挥和相互作用，2）阐明这些基因独立和合作地调节乳腺癌发育，进展和/或耐药性的机制，以及3）建立这些基因在人类乳腺癌中失活的频率和临床环境。这项工作将是理解为什么特定乳腺癌的子集进步的基础，阐明RAS信号的新方面，并将揭示这些新肿瘤抑制剂如何将RAS与其他信号网络联系起来。